U.S. markets closed

Hepion Pharmaceuticals, Inc. (HEPA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.5500-0.0300 (-1.90%)
At close: 4:00PM EDT

Hepion Pharmaceuticals, Inc.

399 Thornall Street
First Floor
Edison, NJ 08837
United States
732 902 4000

Full Time Employees13

Key Executives

NameTitlePayExercisedYear Born
Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D.Pres, CEO & Director600kN/A1958
Mr. John T. CavanChief Financial Officer406.25kN/A1958
Dr. Daren Ure Ph.D.Chief Scientific OfficerN/AN/AN/A
Sharen PyatetskayaDirector of Investor RelationsN/AN/AN/A
Dr. Daniel Trepanier Ph.D.Sr. VP of Drug Devel.N/AN/AN/A
Dr. Patrick Mayo Ph.D.Sr. VP of Clinical PharmacologyN/AN/AN/A
Dr. Todd M. Hobbs M.D.Chief Medical OfficerN/AN/AN/A
Dr. John Z. Sullivan-BolyaiPart-Time ConsultantN/AN/A1948
Dr. Stephen A. HarrisonMember of Scientific Advisory Board & Consultant Medical DirectorN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Corporate Governance

Hepion Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.